Search - tctmd.com

Displaying 1 - 20 of 984

Sort: Relevancy | Date

Financial Support After Hospital Discharge Boosts HFrEF Outcomes: FUND-HF

News Conference News ACC 2026

Financial Support After Hospital Discharge Boosts HFrEF Outcomes: FUND-HF

April 08, 2026

DIG-RHD: Digoxin Effective in Rheumatic Heart Disease

News Conference News ACC 2026

DIG-RHD: Digoxin Effective in Rheumatic Heart Disease

Michael O'Riordan

April 06, 2026

Despite Guidelines, Aspirin Is Used in Fewer Than One in Four High-risk Pregnancies

News Conference News ACC 2026

Despite Guidelines, Aspirin Is Used in Fewer Than One in Four High-risk Pregnancies

Yael L. Maxwell

April 03, 2026

Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b

News Conference News ACC 2026

Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b

Yael L. Maxwell

April 01, 2026

Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering

News Conference News ACC 2026

Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering

Michael O'Riordan

April 01, 2026

SCOUT-HCM: Mavacamten Can Benefit Teens With Obstructive HCM, Too

News Conference News ACC 2026

SCOUT-HCM: Mavacamten Can Benefit Teens With Obstructive HCM, Too

March 30, 2026

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

News Conference News ACC 2026

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

Michael O'Riordan

March 30, 2026

SPIRIT-HF: Spironolactone’s Benefit Still Uncertain in HF With Preserved, Mildly Reduced EF

News Conference News ACC 2026

SPIRIT-HF: Spironolactone’s Benefit Still Uncertain in HF With Preserved, Mildly Reduced EF

March 29, 2026

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

News Conference News ACC 2026

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Michael O'Riordan

March 29, 2026

Barbershop Effort Falls Short for Hypertension Prevention in Black Men

News Conference News ACC 2026

Barbershop Effort Falls Short for Hypertension Prevention in Black Men

March 29, 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

News Conference News ACC 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Yael L. Maxwell

March 28, 2026

KARDINAL: Monthly Tonlamarsen May Not Enhance BP Lowering in Resistant Hypertension

News Conference News ACC 2026

KARDINAL: Monthly Tonlamarsen May Not Enhance BP Lowering in Resistant Hypertension

March 28, 2026

CHAMPION-AF: A Win for Watchman FLX, but With Caveats

News Conference News ACC 2026

CHAMPION-AF: A Win for Watchman FLX, but With Caveats

March 28, 2026

Mechanical Circulatory Support Doesn’t Reduce Infarct Size in STEMI

News Conference News ACC 2026

Mechanical Circulatory Support Doesn’t Reduce Infarct Size in STEMI

Michael O'Riordan

March 28, 2026

What’s Going to Be Hot at ACC 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

TAVR-MET: Early Signs Point to Less Postprocedural Valve Dysfunction With Tirzepatide

News Conference News CRT 2026

TAVR-MET: Early Signs Point to Less Postprocedural Valve Dysfunction With Tirzepatide

March 19, 2026

Large Variability in Use of Invasive Strategy for Type 1 NSTEMI: NCDR

News Conference News CRT 2026

Large Variability in Use of Invasive Strategy for Type 1 NSTEMI: NCDR

Michael O'Riordan

March 11, 2026

DOBERMANN: Dobutamine and Tocilizumab Show Promise in Pre-Shock Patients

News Conference News CRT 2026

DOBERMANN: Dobutamine and Tocilizumab Show Promise in Pre-Shock Patients

March 09, 2026

Baroreflex Activation for Advanced HF Yields Positive Results: Postmarketing Data

News Conference News THT 2026

Baroreflex Activation for Advanced HF Yields Positive Results: Postmarketing Data

March 05, 2026

CRT 2026: What to Expect in Washington, DC

News Conference News CRT 2026

CRT 2026: What to Expect in Washington, DC

March 04, 2026

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.